Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent (Q37783616)

23 August 2017

title

Combretastatin A4 phosphate: a novel vascular disrupting agent (English)

1 reference

23 August 2017

Combretastatin A4 Phosphate: A Novel Vascular Disrupting Agent (English)

1 reference

2 July 2024

author name string

Govardhanan Nagaiah

1

1 reference

23 August 2017

Scot C. Remick

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20799867

2 July 2024

language of work or name

English

0 references

publication date

1 August 2010

1 reference

full work available at URL

23 August 2017

http://www.futuremedicine.com/doi/abs/10.2217/fon.10.90

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:20799867

https://www.tandfonline.com/doi/pdf/10.2217/fon.10.90

2 July 2024

1 reference

2 July 2024

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

8

1 reference

23 August 2017

page(s)

1219-1228

1 reference

Tumor angiogenesis: therapeutic implications

23 August 2017

cites work

1 reference

Endothelial cell proliferation as a novel approach to targeting tumour therapy

21 January 2018

1 reference

Vascular targeting agents as cancer therapeutics

21 January 2018

1 reference

Targeting tumour vasculature: the development of combretastatin A4.

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance

21 January 2018

1 reference

Medical care in long-term survivors of childhood cancer: a report from the childhood cancer survivor study

21 January 2018

1 reference

Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate

21 January 2018

1 reference

Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors

21 January 2018

1 reference

Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors.

21 January 2018

1 reference

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

21 January 2018

1 reference

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer.

21 January 2018

1 reference

ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature.

21 January 2018

1 reference

Relationship between tumour endothelial cell apoptosis and tumour blood flow shutdown following treatment with the antivascular agent DMXAA in mice

21 January 2018

1 reference

Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid

21 January 2018

1 reference

Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer

21 January 2018

1 reference

Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4.

21 January 2018

1 reference

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

21 January 2018

1 reference

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug

21 January 2018

1 reference

Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling

21 January 2018

1 reference

Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy

21 January 2018

1 reference

Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow

21 January 2018

1 reference

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results

21 January 2018

1 reference

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer

21 January 2018

1 reference

Phase I trial of combretastatin a-4 phosphate with carboplatin

21 January 2018

1 reference

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

21 January 2018

1 reference

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome

21 January 2018

1 reference

Cardiovascular safety profile of combretastatin a4 phosphate in a single-dose phase I study in patients with advanced cancer

21 January 2018

1 reference

Targeting the tumor blood vessel network to enhance the efficacy of radiation therapy

21 January 2018

1 reference

Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth

21 January 2018

1 reference

Inhibition of proliferative retinopathy by the anti-vascular agent combretastatin-A4.

21 January 2018

1 reference

Combretastatin A-4 phosphate suppresses development and induces regression of choroidal neovascularization

21 January 2018

1 reference

The microtubule-targeting agent CA4P regresses leukemic xenografts by disrupting interaction with vascular cells and mitochondrial-dependent cell death

21 January 2018

1 reference

Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review.

21 January 2018

4

1 reference

Leukemia regression by vascular disruption and antiangiogenic therapy

2 July 2024

13

1 reference

Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin

2 July 2024

24

1 reference

CD105/smooth muscle actin double immunostaining discriminate between immature and mature tumor blood vessels.

2 July 2024

26

1 reference

Induction of apoptosis in proliferating human endothelial cells by the tumor-specific antiangiogenesis agent combretastatin A-4.

2 July 2024

27

1 reference

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.

2 July 2024

32

1 reference

The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors

2 July 2024

34

1 reference

A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer.

2 July 2024

35

1 reference

A novel K channel blocker isolated from 'hiccup nut' toxin

2 July 2024

46

1 reference

Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).

2 July 2024

51

1 reference

2 July 2024

Identifiers

DOI

10.2217/FON.10.90

1 reference

release_xlayohjskzdvzdhqdfyv6ehc7y

23 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xlayohjskzdvzdhqdfyv6ehc7y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference